16 completed. 16 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 16 |
| Phase 2 | 1 | Completed 1 |
Follow Dermatitis, Contact: new trials by email Literature Review of Dermatitis, Contact trials Research Report on Dermatitis, Contact
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Silk Scaffold Surgical Incision Dressing Dermabond Prineo Skin Closure System, silk, 3M Steri-Strip - Surgical Incision | Phase 1 | Completed | Mehrdad Mark Mofid | 78 | 2022-08-23 | 2024-04-18 |
| Safety Evaluation of KX01 Ointment 1% in Japanese Healthy Male Subjects KX01 ointment 1%, Placebo ointment - Healthy Volunteer | Phase 1 | Completed | PharmaEssentia | 20 | 2021-11-16 | 2022-02-18 |
| Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream MC2-01 Cream, irradiation, MC2-01 Cream, no irradiation, MC2-01 vehicle, irradiation - Phototoxicity | Phase 1 | Completed | MC2 Therapeutics | 35 | 2019-02-27 | 2020-02-12 |
| Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream Induction: Application of MC2-01 Cream, irradiation, Induction: Application of MC2-01 Cream, no irradiation, Induction: Applications of MC2-01 vehicle, irradiation - Photoallergy | Phase 1 | Completed | MC2 Therapeutics | 58 | 2019-02-13 | 2020-03-11 |
| Sensitization Study of ATx201 in Healthy Volunteers ATx201, ATx201 Placebo Gel - Sensitivity, Contact | Phase 1 | Completed | UNION therapeutics | 240 | 2018-01-08 | 2018-05-07 |
| Evaluation of Safety and Efficacy of BBI-2000 in Treating and Preventing Contact Dermatitis BBI-2000, Vehicle, Multiple treatments - Contact Dermatitis | Phase 1 | Completed | Fresh Tracks Therapeutics, Inc. | 47 | 2017-03-14 | 2017-07-17 |
| A Phase I, Single-Center Study of PDC-APB in Healthy Volunteers PDC-APB, Placebo - Contact Dermatitis | Phase 1 | Completed | Hapten Sciences, Inc. | 40 | 2016-03-01 | 2018-02-23 |
| Effect of RANKL Inhibition on UV-induced Immunosuppression Denosumab, UVB exposure, Diphenylcyclopropenone - Ultraviolet Rays, Immunosuppression | Phase 1 | Completed | Innovaderm Research Inc. | 31 | 2013-11-01 | 2014-07-24 |
| Safety, Tolerability, and Efficacy of 21 Days Dermal Application of MRX-6 on Mild to Moderate Contact Dermatitis MRX-6, Steroid - Allergic Contact Dermatitis | Phase 1 / Phase 2 | Completed | Hadassah Medical Organization | 13 | 2011-03-01 | 2015-04-21 |
| TMC435-TiDP16-C125 - Study in Healthy Volunteers to Evaluate the Potential of TMC435 to Increase the Sensitivity of the Skin Towards Exposure to Sun Light TMC435, Placebo, Ciprofloxacin - Hepatitis C Virus | Phase 1 | Completed | Tibotec Pharmaceuticals, Ireland | 49 | 2010-07-01 | 2013-05-06 |
| A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers Tazarotene Foam without irradiation, Tazarotene Foam with UVA and UVB irradiation, Tazarotene Foam with UVA, UVB, and visible light - Acne Vulgaris | Phase 1 | Completed | Stiefel, a GSK Company | 38 | 2010-04-01 | 2017-06-20 |
| Clinical Evaluation of the Phototoxic Potential of Xenaderm Ointment Xenaderm, Placebo - Healthy | Phase 1 | Completed | Healthpoint | 38 | 2008-02-01 | 2014-01-13 |
| Clinical Evaluation of the Photoallergy Potential of Atralin Gel Atralin (tretinoin) gel, 0.05% - Healthy | Phase 1 | Completed | Coria Laboratories, Ltd. | 40 | 2008-01-01 | 2008-05-06 |
| Novel Topical Treatment of Hand Dermatitis (Eczema) Epikeia Coatings - Contact Dermatitis, Eczema, Contact | Phase 1 | Completed | Biomedical Development Corporation | 30 | 2006-08-01 | 2010-03-08 |
| CP-481,715 Nickel Allergy Study. CP-481,715 - Dermatitis, Allergic Contact | Phase 1 | Completed | Pfizer | 48 | 2003-09-01 | 2006-07-25 |
| NI-0801 in Allergic Contact Dermatitis Placebo, NI-0801 - Allergic Contact Dermatitis | Phase 1 | Completed | Light Chain Bioscience - Novimmune SA | 22 | 2010-11-19 |
Dermatitis, Phototoxic (6) · Dermatitis, Allergic Contact (4) · Acne Vulgaris (1) · Dermatitis (1) · Dermatitis, Photoallergic (1) · Eczema (1) · Hepatitis C (1) · Hypersensitivity, Delayed (1) · Photosensitivity Disorders (1) · Surgical Wound (1)
Skin Diseases (16) · Skin Diseases, Eczematous (16) · Skin and Connective Tissue Diseases (16) · Dermatitis (15) · Dermatitis, Irritant (6) · Photosensitivity Disorders (6) · Hypersensitivity (5) · Immune System Diseases (5) · Hypersensitivity, Delayed (4) · Acneiform Eruptions (1) · Blood-Borne Infections (1) · Communicable Diseases (1) · Dermatitis, Allergic Contact (1) · Digestive System Diseases (1)
Radiation (3) · Ciprofloxacin (1) · Denosumab (1) · Exercise (1) · Gels (1) · Granulex (1) · Light (1) · RulB protein, Pseudomonas syringae (1) · Saline Solution (1) · Simeprevir (1) · Sodium Chloride (1) · Steroids (1) · Tretinoin (1) · diphenylcyclopropenone (1) · quinoxaline-2-carboxylic acid (4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyloctyl)amide (1)
MC2 Therapeutics (2) · Biomedical Development Corporation (1) · Coria Laboratories, Ltd. (1) · Fresh Tracks Therapeutics, Inc. (1) · Hadassah Medical Organization (1) · Hapten Sciences, Inc. (1) · Healthpoint (1) · Innovaderm Research Inc. (1) · Light Chain Bioscience - Novimmune SA (1) · Mehrdad Mark Mofid (1) · Pfizer (1) · PharmaEssentia (1) · Stiefel, a GSK Company (1) · Tibotec Pharmaceuticals, Ireland (1) · UNION therapeutics (1)
United States (9) · Canada (2) · Denmark (1) · Israel (1) · Japan (1)
Adelaide A. Hebert, MD (1) · Chad S Boomershine, MD (1) · Hisakuni Sekino (1) · Innes Cargill, PhD (1) · Jonathan S Dorsik (1) · Jonathan S Dosik, MD (1) · Joseph W Stanfield, MS (1) · Lawrence A Romel, MS (1) · Mehrdad Mark Mofid, M.D. (1) · Philippe Prokocimer, MD (1) · Robert Bissonnette, MD (1) · Yuval Ramot, MD (1)